Business Context and Reporting Period
Company: ILLUMINA, INC.
Filing Type: Form 8-K (Current Report)
Date of Report: January 2, 2020
Event: Termination of the Merger Agreement with Pacific Biosciences of California, Inc. ("PacBio").
Key Financial Metrics and Transaction Details
This filing does not report standard operating financial metrics (revenue, profit, cash flow) for a reporting period. Instead, it details specific cash outflows and contingent liabilities associated with the termination of the PacBio merger:
- Reverse Termination Fee: $98 million cash payment to PacBio (due no later than January 6, 2020).
- Continuation Advances: Total of $34 million in cash payments to PacBio:
- $6 million on or before January 2, 2020.
- $22 million on or before February 3, 2020.
- $6 million on or before March 2, 2020.
- Total Immediate Cash Obligation: $132 million ($98 million fee + $34 million advances).
Material Changes and Termination Rationale
The Company and PacBio mutually agreed to terminate the Merger Agreement originally entered into on November 1, 2018. The primary reasons cited for termination are:
- Lengthy regulatory approval processes in both the United States and the United Kingdom.
- Uncertainties regarding the ultimate outcome of the regulatory process.
Contingencies, Repayment Terms, and Outlook
The filing outlines specific conditions under which the payments made to PacBio may be repaid to Illumina:
- Reverse Termination Fee Repayment: If PacBio enters into a definitive agreement for a Change of Control Transaction on or prior to September 30, 2020, PacBio must repay the $98 million fee without interest upon consummation. If the transaction is not consummated within two years of the definitive agreement, repayment is not required.
- Continuation Advances Repayment: Up to the full amount of the $34 million in advances is repayable without interest if, within two years of March 31, 2020, PacBio either:
- Enters into a Change of Control Transaction; or
- Raises at least $100 million in equity or debt financing in a single transaction (repayment amount depends on funds raised).
Investor Verification Checklist
- Verify the exact timing and execution of the $98 million Reverse Termination Fee payment.
- Monitor PacBio's regulatory status and any potential Change of Control transactions through September 30, 2020, which could trigger repayment of the fee.
- Track PacBio's financing activities over the next two years to assess the likelihood of recovering the $34 million in Continuation Advances.
- Review the full text of the Termination Agreement (Exhibit 10.1) for additional covenants or conditions not summarized in this 8-K.